Biora submits updated IND application for ulcerative colitis drug/device trial

Biora Therapeutics has submitted an updated investigational new drug (IND) application with the US Food and Drug Administration (FDA) for…

Microba signs distribution agreement with Sonic for MetaPanel test

Microba Life Sciences has signed a distribution agreement with Sonic Healthcare through its wholly-owned subsidiary Douglass Hanly Moir Pathology, for…

Motus GI concludes initial assessment of device for upper GI procedures

Motus GI and the Ecuadorian Institute of Digestive Diseases (IECED) have completed the initial clinical assessment of the Pure-Vu Gen…

Canadian colonoscopes market set to exceed $65 million by 2030

March is Colorectal Cancer Awareness Month in Canada, where colorectal cancer is second only to lung cancer as the leading…

Olympus joins biliary stent sector – market predicted to be $1bn by 2030

On February 24th, 2023, Olympus Corporation announced it had agreed to acquire Taewoong Medical, a South Korea-based manufacturer specialising in…

Microba Life Sciences unveils next-generation testing product range

Microba Life Sciences has launched its next-generation testing product range, MetaXplore, under Co-Biome, a new brand. Launched in Australia, the…

Boston Scientific to acquire Apollo Endosurgery for $615m

Boston Scientific has signed a definitive agreement to buy minimally invasive medical device company Apollo Endosurgery in a deal valued…

Beyond biopsy: how noninvasive NASH tests can move the needle

Liver biopsy—a process whereby a small piece of liver tissue is extracted via a needle—is the reigning gold standard to…


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.